Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRPS1 | P60891 | 2/20 | 0.45 |
| ▸ | CNR1 | P21554 | 6/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.40 |
| ▸ | HRH2 | P25021 | 3/20 | 0.40 |
| ▸ | CNR2 | P34972 | 8/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5456124 | 0.93 | CNR2 (0.46) | CNR1ACHEHTR4HRH2CNR2 | |
| SCHEMBL14463865 | 0.89 | SMN1; SMN2 (0.40) | CNR1HRH2CNR2SMN1; SMN2ALDH1A1 | |
| SCHEMBL5448665 | 0.88 | CNR2 (0.49) | CNR1HRH2CNR2SMN1; SMN2ALDH1A1 | |
| SCHEMBL5443271 | 0.86 | SMN1; SMN2 (0.55) | CNR1HRH2CNR2SMN1; SMN2ALDH1A1 | |
| SCHEMBL5448593 | 0.85 | ACHE (0.50) | PRPS1CNR1ACHEHTR4HRH2 | |
| SCHEMBL14411094 | 0.84 | CNR2 (0.46) | CNR1ACHEHTR4HRH2CNR2 | |
| SCHEMBL5444562 | 0.83 | CCR1 (0.45) | PRPS1CNR1HRH2CNR2SMN1; SMN2 | |
| SCHEMBL5452607 | 0.83 | PRPS1 (0.43) | PRPS1CNR1CNR2SMN1; SMN2ALDH1A1 | |
| SCHEMBL5461402 | 0.81 | PRPS1 (0.42) | PRPS1CNR1HTR4HRH2CNR2 | |
| SCHEMBL5460523 | 0.80 | CREBBP (0.52) | CNR1CNR2SMN1; SMN2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | PRPS1 4276/4885CNR1 65/4885ACHE 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.